Advent Sold Labormed For $33M, 20% Of Acquisition Price

03.13.2014 By Gabriela Stan

Investment fund Advent sold Romanian generic drug producer Labormed last year to U.S. pharmaceutical company Alvogen for $33 million (EUR24 million), less than 20% of the acquisition price paid back in 2008, according to EY data.

To read the full story, please login. Not a member? Subscribe here.

Reveal Romania! Business news & views.
Find out all you need by reading the entire story
To invest in Romania, you need to find out about its opportunities.
To close a strategic partnership with a Romanian company, you need to learn about its market position and whether it is a trustworthy partner
To grow here, you need to be informed

Subscribe now
Only 50 euros/month (VAT not included)
Get access to reports, news and statistics in the main sectors of Romania’s economy. Follow the strategic moves of companies operating in Romania. We will keep you updated on the latest business events.
Contact: E: newsroom@zfenglish.com (newsroom), marketing@zfenglish.com (Marketing & PR), sales@zfenglish.com (subscriptions)
T: 0040-318.256.431 (Newsroom)
0040-318.256.158, 0040-318.256.408 (Subscriptions Department)
0040-318.256.469, 0040-318.256.470 (Advertising Sales Department)
0040-318.256.427, 0040-318.256.129 (Marketing & PR)

LOGIN / Lost password?

 
Keywords:
ADVENT
, LABORMED
, ALVOGEN